GLP-1

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

The word Diabetes surrounded by tablets and syringes

NICE backs changes to NHS' diabetes care pathway

New guidance from NICE on type 2 diabetes management will shake up NHS treatment, with wider use of both SGLT2 inhibitors and GLP-1 agonists.

News

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

Novo Nordisk has been criticised by the FDA for a TV ad for the Wegovy pill, which the agency claims makes "false and misleading" claims.

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

AstraZeneca raises guidance on stellar cancer drugs growth

AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.

After CagriSema blow, Novo reveals data for obesity 'triple'

Head-to-head trial dents Novo Nordisk's obesity hopes

NICE backs changes to NHS' diabetes care pathway

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

Kailera, Hengrui stake claim to oral weight loss category

AstraZeneca raises guidance on stellar cancer drugs growth

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

GLP-1

Editor's Picks